Publish in this journal
Journal Information
Vol. 71. Issue 3.
Pages 228-229 (March 2018)
Share
Share
Download PDF
More article options
Vol. 71. Issue 3.
Pages 228-229 (March 2018)
Scientific letter
DOI: 10.1016/j.rec.2017.10.053
Full text access
Selection of the Best of 2017 on the Usefulness of Cardiac Stimulation in the Treatment of Vasovagal Syncope
Selección de lo mejor del año 2017 sobre la utilidad de la estimulación cardiaca en el tratamiento del síncope vasovagal
Visits
...
Gonzalo Barón-Esquiviasa,
Corresponding author
, Carlos A. Morillob, Angel Moya-Mitjansc, Jesús Martínez-Aldayd,e, Ricardo Ruiz-Granellf, Javier Lacunza-Ruizg
a Servicio de Cardiología y Cirugía Cardíaca, Hospital Universitario Virgen del Rocío, Universidad de Sevilla, Sevilla, Spain
b Department of Cardiac Sciences, Libin Cardiovacular Institute of Alberta, University of Calgary and Population Health Research Institute-McMaster University, Hamilton, Canada
c Servicio de Cardiología, Hospital Universitario Vall d’Hebron, Barcelona, Spain
d Servicio de Cardiología, Hospital Universitario Basurto, Bilbao, Spain
e Servicio de Cardiología, Clínica IMQ Zorrotzaurre, Bilbao, Spain
f Servicio de Cardiología, Hospital Universitario Clínico de Valencia, Valencia, Spain
g Servicio de Cardiología, Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain
Related content
Rev Esp Cardiol. 2018;71:229-3110.1016/j.rec.2017.10.051
María José Sancho-Tello de Carranza, Óscar Cano Pérez, Joaquín Osca Asensi, Diego Lorente Carreño, Marta Pombo Jiménez, María Luisa Fidalgo Andrés
Article information
Full Text
Bibliography
Download PDF
Statistics
Full Text
To the Editor,

During 2016 and 2017, 5 papers have been published on recurrent vasovagal syncope with cardioinhibitory response to the tilt table test (TTT) and treatment with pacemaker implantation.

The first paper reported on a single center, retrospective, observational study of 24 patients with recurrent syncope. An in-depth diagnostic protocol was applied, including a TTT and exclusion of any other cause for syncope, followed by insertion of an implantable loop recorder (ILR). When patients then had a first syncope recurrence accompanied by asystole longer than 3 seconds or asystole longer than 6 seconds irrespective of syncope recurrence, they received a dual-chamber pacemaker with rate drop response (RDR). In the 35-month follow-up, syncope recurred in 7 patients, 4 of whom were TTT-positive. However, of the 17 patients without syncope recurrence, the TTT was positive in only 2.1

The second paper described a prospective, multicenter study with 281 patients older than 40 years who underwent a diagnostic study starting with carotid sinus massage (CSM). Of these patients, 78 had asystole and were given an implantable PM. The remaining 203 patients underwent a TTT. A VASIS type 2B response with asystole was induced in 38 patients, who were then given an implantable PM. The remaining 165 patients received an ILR. Asystole was recorded in 21 of these patients, who were then given an implantable PM. All 137 patients treated with a PM received a dual-chamber device with rate drop sensing to allow minimal ventricular pacing time. Syncope recurred in 25 of the 281 patients (18%), and there were no differences according to the test (CSM, TTB or ILR) that indicated PM requirement. At 3 years of follow-up, 20% of the 137 patients with a PM had had syncope recurrence, which was significantly lower than the 43% in the 142 patients who received no PM (P=.01). Among the patients who had asystole during the TTT, syncope recurrence was 3% at 12 months and 17% at 21 months. Among the patients with a negative TTT, syncope recurrence was only 5% at 3 years.2

The third paper reported on a multicenter, prospective, single-blind, randomized study that enrolled 30 patients with a dual-chamber PM with closed-loop stimulation (CLS) implanted at least 6 months prior to enrolment, with a history of recurrent syncopes and cardioinhibitory response to the TTT. At the initial visit, patients were randomized 1:1 by a central system into 1 of 2 pacing groups, DDD-CLS first or DDD first (at a fixed rate of 60 bpm), and they underwent a first TTT with the PM activated. At the end of the test, the PM was reprogrammed and 1 week later, the test was repeated with the other pacing mode, i.e., with crossover from DDD-CLS to DDD and from DDD to DDD-CLS. Compared with DDD, the DDD-CLS mode significantly reduced the occurrence of syncope in the TTT (30.0% vs 76.7%; P <.001). Among the patients who had a syncope in both TTTs and with both pacing modes, DDD-CLS significantly delayed the onset of syncope during TTT. The maximum fall in blood pressure recorded during the TTT was significantly lower in DDD-CLS than in DDD.3

The fourth paper described the SPAIN study, with a multicenter, prospective, randomized, double-blind design, that enrolled 54 patients with recurrent syncope and TTT cardioinhibitory response. A total of 46 patients completed the protocol. All patients received a DDD-CLS PM and were randomized 1:1 to 2 groups: group A first received DDD-CLS for 12 months and then DDI for 12 months; group B first received DDI and then DDD-CLS for the same periods of time as group A. During 22 months of follow-up, in group A, 72% of patients receiving DDD-CLS therapy had ≥ 50% reduction in syncopes versus 28% of patients receiving DDI; and in group B, all patients had ≥ 50% reduction in syncopes after switching from DDI mode to DDD-CLS in the second year (P=.0003). Just 4 patients (8.7%) had a syncope when in DDD-CLS mode, versus 21 (45.65%) who had one when in DDI mode (hazard ratio=6.72; odds ratio=0.11; P <.0001). The Kaplan-Meier analysis showed significantly longer time to first syncope in group A versus group B and the same finding was also observed in the 46 patients in DDD-CLS mode versus DDI mode (P <.0001). Therefore, DDD-CLS pacing significantly reduces syncope burden, lowers syncope recurrence 7-fold, and significantly prolongs time to first recurrence.4,5 The BIOSync study, 6the fifth paper referred to here, aims to confirm our results.

.

References
[1]
M. Tomaino, M. Unterhuber, P. Sgobino, F. Pescoller, M. Manfrin, W. Rauhe.
Combined diagnostic yield of tilt table test and implantable loop recorder to identify patients affected by severe clinical presentation of neurally-mediated reflex syncope who could respond to cardiac pacing.
J Atr Fibrillation., 8 (2016), pp. 1397
[2]
M. Brignole, F. Arabia, F. Ammirati, on behalf of the Syncope Unit Project 2 (SUP 2) investigators, et al.
Standardized algorithm for cardiac pacing in older patients affected by severe unpredictable réflex syncope: 3-year insights from the Syncope Unit, Project 2 (SUP 2) study.
Europace., 18 (2016), pp. 1427-1433
[3]
P. Palmisano, G. Dell’Era, V. Russo, et al.
Effects of closed-loop stimulation vs, DDD pacing on haemodynamic variations and occurrence of syncope induced by head-up tilt test in older patients with refractory cardioinhibitory vasovagal syncope: the Tilt test-Induced REsponse in Closed-loop Stimulation multicentre, prospective, single blind, randomized study.
Europace., (2017),
Available from: https://doi.org/10.1093/europace/eux015 Accessed 26 Oct 2017.
[4]
G. Baron-Esquivias, C.A. Morillo, A. Moya-Mitjans, et al.
Dual-chamber pacing with closed loop stimulation in recurrent reflex vasovagal syncope, The SPAIN Study.
J Am Coll Cardiol., 70 (2017), pp. 1720-1728
[5]
G. Barón-Esquivias, C.A. Morillo.
La estimulación definitiva en el paciente con síncope Neuromediado, Lecciones del estudio SPAIN.
Rev Esp Cardiol., (2017),
[en prensa]
[6]
M. Brignole, M. Tomaino, A. Aerts, et al.
Benefit of dual-chamber pacing with Closed Loop Stimulation in tilt-induced cardio-inhibitory reflex syncope (BIOSync trial): study protocol for a randomized controlled trial.
Available from: https://doi.org/10.1186/s13063-017-1941-4. Accessed 26 Oct 2017
Copyright © 2017. Sociedad Española de Cardiología
Idiomas
Revista Española de Cardiología (English Edition)

Subscribe to our newsletter

Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?